St. Lukes' Survey on vaccination coverage

St. Lukes hospital, a PRAM unit in Zomba district, had an estimated vaccination coverage of 44% in 1990. To conf"1rID this very low coverage, a survey was done in the 5 km catchment area around the hospital. 611 children, being 104% of the estimated number, bom between 1st June 1989 and 31st May 1990 were checked for vaccination status and the type of unit where they received the vaccinations. 593 (97.1%) appeared to be fully immunised; 13 (2.1%) had lost their card; 3 (0.5%) had partial immunisation and 2 (0.3%) had not received any vaccination. 54.2% of all vaccinations were given through outreach clinics; 33.7% in the hospital; 11.8 % in health centres and 0.3% in private units.- This survey shows in the fIrst place that an estimated vaccination coverage can give a very poor picture of the real situation. In the second place it shows the importance of outreach clinics as a means of improving immunisation activities

Effectiveness and costs of implementation strategies to reduce acid suppressive drug prescriptions: a systematic review

<p>Abstract</p> <p>Background</p> <p>Evaluation of evidence for the effectiveness of implementation strategies aimed at reducing prescriptions for the use of acid suppressive drugs (ASD).</p> <p>Methods</p> <p>A systematic review of intervention studies with a design according to research quality criteria and outcomes related to the effect of reduction of ASD medication retrieved from Medline, Embase and the Cochrane Library. Outcome measures were the strategy of intervention, quality of methodology and results of treatment to differences of ASD prescriptions and costs.</p> <p>Results</p> <p>The intervention varied from a single passive method to multiple active interactions with GPs. Reports of study quality had shortcomings on subjects of data-analysis. Not all outcomes were calculated but if so rction of prescriptions varied from 8% up to 40% and the cost effectiveness was in some cases negative and in others positive. Few studies demonstrated good effects from the interventions to reduce ASD.</p> <p>Conclusion</p> <p>Poor quality of some studies is limiting the evidence for effective interventions. Also it is difficult to compare cost-effectiveness between studies. However, RCT studies demonstrate that active interventions are required to reduce ASD volume. Larger multi-intervention studies are necessary to evaluate the most successful intervention instruments.</p

Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website (MIBS trial)

Background: IBS affects 10-22% of the UK population. Abdominal pain, bloating and altered bowel habit affectquality of life, social functioning and time off work. Current GP treatment relies on a positive diagnosis, reassurance,lifestyle advice and drug therapies, but many suffer ongoing symptoms. A recent Cochrane review highlighted the lack of research evidence for IBS drugs. Neither GPs, nor patients have good evidence to inform prescribing decisions. However, IBS drugs are widely used: In 2005 the NHS costs were nearly £10 million for mebeverine and over £8 million for fibre-based bulking agents. CBT and self-management can be helpful, but poor availability in the NHS restricts their use. We have developed a web-based CBT selfmanagement programme, Regul8, based on an existing evidence based self-management manual and in partnership with patients. This could increase access with minimal increased costs.Methods/Design: The aim is to undertake a feasibility factorial RCT to assess the effectiveness of the commonlyprescribed medications in UK general practice for IBS: mebeverine (anti-spasmodic) and methylcellulose(bulkingagent)and Regul8, the CBT based self-management website. 135 patients aged 16 to 60 years with IBS symptoms fulfilling Rome III criteria, recruited via GP practices, will be randomised to 1 of 3 levels of the drug condition: mebeverine, methylcellulose or placebo for 6 weeks and to 1 of 3 levels of the website condition, Regul8 with a nurse telephone session and email support, Regul8 with minimalemail support, or no website, thus creating 9 groups.Outcomes: Irritable bowel symptom severity scale and IBS-QOL will be measured at baseline, 6 and 12 weeks asthe primary outcomes. An intention to treat analysis will be undertaken by ANCOVA for a factorial trial.Discussion: This pilot will provide valuable information for a larger trial. Determining the effectiveness ofcommonly used drug treatments will help patients and doctors make informed treatment decisions regarding drugmanagement of IBS symptoms, enabling better targeting of treatment. A web-based self-management CBT programme for IBS developed in partnership with patients has the potential to benefit large numbers of patients with low cost to the NHS. Assessment of the amount of email or therapist support required for the website willenable economic analysis to be undertaken.Trial Registration: ClinicalTrials.gov Identifier (NCT number): NCT00934973